International Conference on Harmonisation; draft guidance on E2F Development Safety Update Report; availability. Notice.
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled "E2F Development Safety Update Report." The draft guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The draft guidance describes the format, content, and timing of a development safety update report (DSUR) for an investigational drug. The DSUR would serve as a harmonized, annual clinical trial safety report that would be standard among the three ICH regions. The DSUR could be submitted in the United States in place of an annual report for an investigational new drug application (IND). The harmonized DSUR is intended to promote a consistent approach to annual clinical safety reporting among the ICH regions and enhance efficiency by reducing the number of reports generated for submission to the regulatory authorities.
D001688:Biological Products / Q000592:standards*; D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence*; D002986:Clinical Trials as Topic / Q000592:standards; D003226:Congresses as Topic; D004282:Documentation / Q000379:methods; D015507:Drugs, Investigational / Q000592:standards*; D005062:European Union; D006801:Humans; D007391:International Cooperation / Q000331:legislation & jurisprudence*; D007564:Japan; D012449:Safety; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products; D015507:Drugs, Investigational